Latest Us Market News

US1 Critical Minerals has obtained a Federal Court undertaking preventing the transfer or encumbrance of disputed Rare Earth tenements in California, with a trial scheduled for April 2026.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Calix Limited has landed a significant three-year contract with a major US agriculture company, potentially adding up to A$10 million in annual revenue starting early 2026.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Talga Group has opened a $5 million Share Purchase Plan at $0.41 per share, offering shareholders free attaching and piggyback options to support its planned anode production ramp-up and US expansion.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Adherium Limited reports a remarkable 103% quarter-on-quarter growth in Remote Patient Monitoring subscription revenues for Q2 FY26, driven by strong device shipment momentum and strategic operational changes.

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

Ovanti’s US payments brand Flote has partnered with cloud-native platform Gr4vy to launch scalable, responsible buy now pay later solutions in the US market starting 2026.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.

Vection Technologies reports a record quarter-to-date cash intake of approximately $14 million and a robust $50 million forward pipeline, underscoring strong momentum across defence, AI, healthcare, and retail sectors.